Biodexa Pharmaceuticals (BDRX) Projected to Post Earnings on Friday

Biodexa Pharmaceuticals (NASDAQ:BDRX) is anticipated to release its Q4 2025 results before the market opens on Friday, April 24th. Analysts expect Biodexa Pharmaceuticals to post earnings of ($0.0013) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 27, 2026 at 8:00 AM ET.

Biodexa Pharmaceuticals (NASDAQ:BDRX) last announced its quarterly earnings data on Friday, March 27th. The company reported $3.52 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $3.53. On average, analysts expect Biodexa Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Biodexa Pharmaceuticals Price Performance

NASDAQ:BDRX opened at $3.47 on Friday. Biodexa Pharmaceuticals has a 1 year low of $2.86 and a 1 year high of $96.50. The stock has a 50-day moving average price of $4.50 and a two-hundred day moving average price of $16.84.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on BDRX shares. Wall Street Zen downgraded Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, March 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Hedge Funds Weigh In On Biodexa Pharmaceuticals

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Armistice Capital LLC purchased a new stake in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned approximately 14.71% of Biodexa Pharmaceuticals at the end of the most recent reporting period. 17.51% of the stock is owned by institutional investors.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.